Trial Profile
An exploratory study of MCI-196 [colestilan] for treatment of type 2 diabetes in randomized, double blind, parallel assignment, placebo-controlled manner
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Colestilan (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Mitsubishi Pharma Corporation
- 01 Mar 2010 Secondary endpoint 'Low density lipoprotein cholesterol level' has been met according to results published in Diabetes, Obesity and Metabolism.
- 01 Mar 2010 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to results published in Diabetes, Obesity and Metabolism,
- 01 Mar 2010 Primary endpoint 'Fasting glucose level' has been met according to results published in Diabetes, Obesity and Metabolism.